New Chapter in Theseus’ Adventure as Troubled Biotech Approached by Two Potential Suitors

It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of potential buyers. One of the offers came from the VC firms Foresite and Orbimed. On Nov. 22, the two firms “indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares” of Theseus that they don’t already own, the biotech revealed in a Nov. 27 release. Should Theseus accept that offer, it would take the company—which has been listed on the Nasdaq since October 2021—private again.

Read the full article: New Chapter in Theseus’ Adventure as Troubled Biotech Approached by Two Potential Suitors //

Source: https://www.fiercebiotech.com/biotech/new-chapter-theseus-adventure-troubled-biotech-approached-two-potential-suitors

Leave a Comment

Your email address will not be published.

Scroll to Top